Results 231 to 240 of about 281,370 (287)

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source

Early-Stage Breast Cancer in Women Younger Than 50 Years: Comparing American Joint Committee on Cancer Anatomic and Prognostic Stages With Partitioning Around Medoids Clusters in SEER Data. [PDF]

JCO Clin Cancer Inform
Zulbayar S, Brooks J, Aminoleslami A, Kim S, Calderon Anyosa RJC, Xiang F, Knight J, Eisen A, Anderson GM.   +8 more
europepmc   +1 more source

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

Precision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run, Shiwei Jiang, Kun Xu, Yu Fan, Yanwen Chen, Ziao Liu, Zengli Miao, Wei Tian   +7 more
wiley   +1 more source

Cyclin-Dependent 4/6 Kinase Inhibitors for Treatment of HER2-Positive Breast Cancer: 2026 Update. [PDF]

Cancers (Basel)
O'Sullivan CC.
europepmc   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Historical Perspective of HER2 Testing and Treatment in Prostate Cancer. [PDF]

Curr Oncol
Zamalloa N, Rose J, Lap CJ, Rajendran R, Estephan F, Jatwani K, Poudel A, Subrahmanyam R, Hurley PJ, Nava VE, Jain M.   +10 more
europepmc   +1 more source

Antibody-functionalized nanoporous silicon particles as a selective doxorubicin vehicle to improve toxicity against HER2+ breast cancer cells

Science and Engineering of Composite Materials
Camacho Alma Rosa Oaxaca, Rodríguez Sara Elisa Herrera, Mojica Óscar René Ochoa, Agarwal Vivechana, Pelayo Alexis Jazmín Preciado, Arízaga Gregorio Guadalupe Carbajal, Álvarez Ángel H., Carvajal Zaira Yunuen García, Velázquez Moisés Martínez, Gutiérrez Rodolfo Hernández   +9 more
doaj   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Combining an anti-HER2 antibody-drug conjugate with an anti-nectin-4 antibody-drug conjugate enhances efficacy in breast cancer and gastric cancer models. [PDF]

Cancer Cell Int
Yazdi N, Pourjamal N, Li H, Laakkonen P, Joensuu H, Barok M.   +5 more
europepmc   +1 more source